Chung-Han Lee 李宗翰, MD/PhD
@ChungHanLee3
Followers
699
Following
113
Statuses
214
Physician-Scientist Focused on Biomarker Development and Novel Therapies
New York, NY
Joined March 2019
Rarely do I see such flawed analysis in an abstract that it makes me read the full article. irAEs Can Predict PFS and OS In Patients w/ Metastatic Renal Cell Carcinoma Treated w/ Immune Checkpoint Inhibitors - PubMed (
1
1
3
RT @montypal: Very excited to share with you incredibly promising data for #zanzalintinib (#XL092) in patients with #kidneycancer. A millio…
0
47
0
Great to see everyone at ESMO. @KidneyCancer keep up the good work. Our patients need you.
Enjoyed meeting old friends at #ESMO23, making new connections, seeing practice-changing research, and having lots of great discussions about how to advance #kidneycancer science by and for patients 🤝 see you next year @myESMO!
0
2
10
Ending my last clinic @MSKCancerCenter with dinner with @IyerGopa and @KotechaMD. So grateful to work 12 years with the best mentor I have ever had, @motzermd. So proud of @KellyNFitz who is starting @UCSF . Excited to start a new chapter of my career on 8/14.
10
2
71
So lucky to have had the chance to work with @KellyNFitz. UCSF is so lucky to have you. We are all expecting great things from you.
A life/career update, delayed by a transcontinental move: last month I graduated @MSKCancerCenter fellowship, and this week I joined the GU Med Onc faculty group at @UCSFCancer! Owe so much to my mentors @ChungHanLee3 @motzermd and many others, and so excited for what’s to come.
0
1
14
RT @KellyNFitz: A life/career update, delayed by a transcontinental move: last month I graduated @MSKCancerCenter fellowship, and this week…
0
2
0
RT @VJOncology: 🎥@ChungHanLee3 of @MSKCancerCenter discusses combining lenvatinib and pembrolizumab as a first-line treatment for non-clear…
0
2
0
RT @BrendanGuercio: Thank u @NicoleKuderer! So appreciative of @BladderCancerUS, who supported work with @IyerGopa @ChungHanLee3 showing as…
0
1
0
RT @maughanonc: Thanks @SWOG for highlighting #PAPMET2 as the trial of the week. Prior IO trials suggest it is time for a randomized trial.…
0
2
0
RT @urotoday: #KEYNOTEB61 study reveals promising results of lenvatinib + pembrolizumab combo in non-clear cell #RCC. @ChungHanLee3 @MSKCan…
0
4
0
RT @OncLive: Longer follow-up data from the Study 111/KN146 showed that lenvatinib and pembrolizumab produced durable responses lasting at…
0
2
0
RT @OncLive: Lenvatinib and pembrolizumab continued to show clinical activity in patients with metastatic RCC, including in subsets of pati…
0
4
0
RT @CancerNetwrk: “The responses remained durable in a subset of patients who were previously treated but ICI naïve, but also in patients w…
0
1
0
RT @OncLive: Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups @ChungHanLee3 @MSKCan…
0
2
0
RT @AlbigesL: Pleased to share @TheLancetOncol LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … i…
0
105
0
RT @KidneyCancer: Special thanks to our superstar #IKCSNA23 planning committee! @drphil_urology @TiansterZhang @bergsa83 #MariaCarlo #Dan…
0
5
0
RT @CancerNetwrk: Pembrolizumab plus lenvatinib yielded anti-tumor activity and a manageable safety profile as a first-line treatment optio…
0
1
0
RT @TiansterZhang: @kidneycancer brings together the #kidneycancer community for research & practice updates twice yearly #IKCS symposia. I…
0
6
0
RT @motajmsc: #ASCO2023 Interesting work by @BrendanGuercio, @ChungHanLee3, and colleagues from @MSKCancerCenter showing an association bet…
0
1
0